Artivion (NYSE:AORT) Downgraded by Wall Street Zen to Sell

by · The Cerbat Gem

Wall Street Zen downgraded shares of Artivion (NYSE:AORT – Free Report) from a hold rating to a sell rating in a report issued on Saturday.

AORT has been the subject of a number of other research reports. Weiss Ratings lowered Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday. Canaccord Genuity Group set a $39.00 target price on Artivion in a research report on Friday, August 7th. Citigroup reissued a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Stifel Nicolaus set a $45.00 price target on Artivion in a report on Monday, June 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 price objective on shares of Artivion in a research note on Monday, July 20th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Artivion presently has an average rating of “Moderate Buy” and an average target price of $44.67.

Read Our Latest Stock Analysis on AORT

Artivion Trading Up 2.8%

Artivion stock opened at $29.22 on Friday. Artivion has a 1 year low of $19.16 and a 1 year high of $48.25. The firm’s 50 day moving average price is $24.28 and its 200-day moving average price is $30.59. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51. The stock has a market cap of $1.42 billion, a P/E ratio of -417.33 and a beta of 1.25.

Artivion (NYSE:AORT – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The firm had revenue of $125.76 million during the quarter, compared to analyst estimates of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. On average, equities analysts predict that Artivion will post 0.45 earnings per share for the current fiscal year.

Insider Transactions at Artivion

In other Artivion news, SVP Andrew M. Green sold 44,001 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total transaction of $910,820.70. Following the sale, the senior vice president directly owned 60,259 shares in the company, valued at $1,247,361.30. This represents a 42.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jean F. Holloway sold 977 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total value of $27,834.73. Following the completion of the sale, the senior vice president directly owned 184,118 shares of the company’s stock, valued at $5,245,521.82. The trade was a 0.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 6.30% of the stock is currently owned by company insiders.

Institutional Trading of Artivion

Several hedge funds and other institutional investors have recently bought and sold shares of AORT. Royal Bank of Canada increased its position in Artivion by 107.0% during the first quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock valued at $952,000 after acquiring an additional 20,010 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Artivion by 8.8% during the 1st quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock worth $862,000 after purchasing an additional 2,823 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Artivion by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock worth $580,000 after purchasing an additional 1,032 shares during the period. Creative Planning grew its holdings in Artivion by 5.6% during the 2nd quarter. Creative Planning now owns 14,272 shares of the company’s stock valued at $444,000 after purchasing an additional 753 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in Artivion by 40.8% during the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after purchasing an additional 139,370 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

(Get Free Report)

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

Featured Articles